Viewers skew older, but adults ages 35 to 54 report the strongest purchase intent for brands advertised there.
The most-favored-nation framework extends to nine midsize drugmakers, tying more US pricing decisions to what other countries pay.
Nearly a quarter of physicians (23%) say patients ask them for guidance on using wearable data to manage their health at least once a week, according to a March survey from the American Medical Association.
Gen Z and millennials’ self-care and wellness spending intentions are strong, but their budgets could change, meaning brands must demonstrate tangible value.
Pharma and providers need to help women better understand common overlooked symptoms to make more informed treatment decisions.
Nurses gives healthcare and pharma marketers a credible way to make health content accessible.
Healthcare providers need clearer explanations and consent based on how AI affects care decisions and ongoing treatment.
The deal could set stricter expectations for age checks and outside oversight across social media and tech platforms.
New, affordable GLP-1 access for Medicare beneficiaries creates an opening for marketers to address seniors’ specific weight loss needs.
RevMed’s newly approved drug nearly doubles median survival in Stage 4 pancreatic cancer, showing that a less-established biotech can succeed where larger drugmakers have struggled.
11% of US adults currently use a GLP-1 medication, up from just 3% two years earlier, according to a July report from Gallup.
As employer health costs climb, reduced coverage for weight loss drugs will expand the self-pay GLP-1 market and intensify price competition among drugmakers.
Ecommerce plays a bigger role in purchasing health products than in discovery of them, giving brands an opportunity to convert in-store trial into online demand.
Brand and side-effect questions prompt longer-than-average chats, raising the value of comprehensive information as consumers weigh treatments.
Their new FDA-cleared test could help identify more Alzheimer’s patients and bring detection out of the specialists' office and into routine primary care.
Tech advocates see AI autonomy in medicine, but doctors’ safety, liability, and control concerns will stand in the way.
Consumers budget for weight loss as they cut spending elsewhere. Gyms, drugmakers, and supplement brands can build on that commitment with services supporting long-term health goals.
Drug price negotiations helped lower overall prices, but many patients still don't feel savings at the counter.
Consumers want simpler snack labels, but not at the sacrifice of taste and quality.
Drug pricing and TrumpRx questions eat into valuable doctor time. Drugmakers need to guide consumers to the right Rx resources.